期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 29, 期 29, 页码 4499-4527出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v29.i29.4499
关键词
Energy metabolism; Mitochondria; Hypoxia; Oxidative phosphorylation; Glycolysis; Gastrointestinal neoplasms
This review summarizes the metabolic reprogramming and bioenergetic alterations in gastrointestinal (GI) cancers, highlighting the interplay between different metabolic pathways and their oncogenetic links. It emphasizes the potential of targeting bioenergetic regulators for anti-cancer therapy, provides details on various anti-cancer drugs and strategies, and discusses the challenges faced by targeted therapies due to the diverse metabolic patterns. Further research is needed to understand specific mechanisms of inhibiting bioenergetic enzymes and address side effects, as well as leverage omics technologies for targeted bioenergetic therapies.
Cancer cells exhibit metabolic reprogramming and bioenergetic alteration, utilizing glucose fermentation for energy production, known as the Warburg effect. However, there are a lack of comprehensive reviews summarizing the metabolic reprogramming, bioenergetic alteration, and their oncogenetic links in gastrointestinal (GI) cancers. Furthermore, the efficacy and treatment potential of emerging anticancer drugs targeting these alterations in GI cancers require further evaluation. This review highlights the interplay between aerobic glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation (OXPHOS) in cancer cells, as well as hypotheses on the molecular mechanisms that trigger this alteration. The role of hypoxia-inducible transcription factors, tumor suppressors, and the oncogenetic link between hypoxia-related enzymes, bioenergetic changes, and GI cancer are also discussed. This review emphasizes the potential of targeting bioenergetic regulators for anti-cancer therapy, particularly for GI cancers. Emphasizing the potential of targeting bioenergetic regulators for GI cancer therapy, the review categorizes these regulators into aerobic glycolysis/ lactate biosynthesis/transportation and TCA cycle/coupled OXPHOS. We also detail various anti-cancer drugs and strategies that have produced pre-clinical and/or clinical evidence in treating GI cancers, as well as the challenges posed by these drugs. Here we highlight that understanding dysregulated cancer cell bioenergetics is critical for effective treatments, although the diverse metabolic patterns present challenges for targeted therapies. Further research is needed to comprehend the specific mechanisms of inhibiting bioenergetic enzymes, address side effects, and leverage high-throughput multi-omics and spatial omics to gain insights into cancer cell heterogeneity for targeted bioenergetic therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据